Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02818023
Title Dose-seeking Study of Pembrolizumab Plus Vemurafenib and Cobimetinib Advanced Melanoma
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors University of Pittsburgh

mucosal melanoma

skin melanoma



Cobimetinib + Pembrolizumab + Vemurafenib

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST